Early immunotherapy shows strong responses in advanced basal cell carcinoma
Johns Hopkins Medicine - 18-Nov-2025First-line nivolumab doubles typical response rates in inoperable basal cell carcinoma
The Live Forever Club is evolving. Subscribe to the newsletter to be the first to hear about this important change.
First-line nivolumab doubles typical response rates in inoperable basal cell carcinoma
Scientists believe this treatment could one day help prevent and treat common skin cancers
AI apps can be inefficient in skin cancer diagnosis, if not properly regulated and certified
No resources found!
No blog posts found!